Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Scandinavian Real Heart AB (Publ) is a Swedish medical technology company specializing in the design and development of an innovative artificial heart. Its flagship product, the Realheart Total Artificial Heart (TAH), is engineered to closely mimic the structure and pulsatile function of the human heart, aiming to treat patients with advanced-stage heart failure. Founded in 1999, the company partners with leading cardiac surgeons and researchers globally to advance its preclinical and clinical development programs. Realheart's technology seeks to address the critical global need for effective bridge-to-transplant therapies, offering a potentially revolutionary alternative to current heart pump systems by significantly reducing blood cell damage and improving patient survival and quality of life. The company operates with a strategic focus on clinical trials, regulatory approvals, and scalable production, targeting a substantial global market for heart failure treatment. With a strong management team and ongoing collaborations, Scandinavian Real Heart AB contributes to the legacy of Swedish innovation in life-saving medical devices.
kr 1.89
kr 0.02 (-1.05%)
EOD Jun 23, 2026 · Twelve Data
ROIC dropped from -15.08% to -17.33%, capital efficiency is deteriorating. Negative free cash flow of -kr 44M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 0.00
Net Income (TTM)
-kr 35M
▼ -3.3% YoY
Op. Margin
—
ROIC
-17.33%
▼ -2.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 44M
▼ -6.3% YoY
Op. Cash Flow (TTM)
-kr 36M
▼ -7.5% YoY
Net Debt
-kr 12M
Net Cash Position
Cash & Equiv.
kr 17M
Continue Research
Scandinavian Real Heart AB (Publ) (HEART.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Scandinavian Real Heart AB (Publ) scores 10/100 on Intrinsiqq's quality scorecard, weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Scandinavian Real Heart AB (Publ) scores 10 out of 100 on Intrinsiqq's quality score, passing 1 of 4 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -17.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh HEART.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.